Abstract:Background: Zinc finger protein 500 (ZNF500) has an unknown expression pattern and biological function in human tissues. This study was designed to determine what role ZNF500 played in breast cancer progression and chemotherapy resistance. Methods: Firstly, we assessed the expression pattern of ZNF500 by bioinformatics assay and immunohistochemistry staining. Colony formation assay, MTT assay, EdU assay, flow cytometric analysis, western blotting analysis, mice xenograft model, immunofluorescence assay, RT-PCR, PCR-array, GST-pull down assay and immunoprecipitation assay were performed to investigate the effect of ZNF500 on proliferation, chemotherapy sensitivity and P53-P21-E2F4 signaling axis activation. Secondly, we constructed ZNF500-ΔC2H2, ZNF500-ΔSCAN,ZNF500-ΔKRAB, P53-ΔC, P53-ΔDBD, P53-ΔN mutant plasmids. Immunoprecipitation assay, GST-pull down assay, and western blotting analysis were performed to evaluate interaction among ZNF500, P53 and MDM2, as well as their impact on chemotherapy sensitivity. Finally, immunohistochemistry analysis was used to assess the expression of ZNF500, P53 and E2F4 in clinical tissue samples and its correlation with chemotherapy resistance. Results: We found that ZNF500 was highly expressed in breast cancer, but negatively correlated with advanced TNM stage, lymph node metastasis and poor prognosis. ZNF500 overexpression abolished in vivo and in vitro breast cancer cell proliferation by activating the p53-p21-E2F4 signaling axis and directly interacted with p53 via its C2H2 domain. This may prevent ubiquitination of p53 in a manner that is competitive to MDM2, thus stabilizing p53. When ZNF500-∆C2H2 was overexpressed, suppressed proliferation of breast cancer cells was neutralized in vitro and in vivo . In human breast cancer tissues, ZNF500 expression was positively correlated with p53and E2F4 expression. ZNF500 expression was significantly lower in patients with Miller/Payne Grade 1–2 than that in those with Miller/PayneGrade 3–5. Conclusions: Our data suggest that ZNF500 can directly bind to the C-terminal of p53 via its C2H2 domain. This interaction may prevent ubiquitin-mediated degradation by MDM2, thus abrogating the proliferation of breast cancer cells, strengthening DNA damage, and sensitizing breast cancer patients to chemotherapy.

ZNF498 promotes hepatocellular carcinogenesis by suppressing p53-mediated apoptosis and ferroptosis via the attenuation of p53 Ser46 phosphorylation

Abstract 830: ZFP14, a p53 target, suppresses tumor formation by regulating HOXA gene cluster expression

Zinc Finger Protein 296 Promotes Hepatocellular Carcinoma Progression Via Intervening Interaction Between Macrophages and B Cells.

STAT1 Inhibits Human Hepatocellular Carcinoma Cell Growth Through Induction of P53 and Fbxw7

ZNF500 Suppresses the Proliferation of Breast Cancer Cells and Sensitizes Them to Chemotherapy by Stabilizing P53 in a Manner That is Competitive to MDM2

ZNF143-Mediated H3K9 Trimethylation Upregulates CDC6 by Activating MDIG in Hepatocellular Carcinoma

Abstract 1482: FKBP52 drives diverse HCC phenotypes through context-dependent targeting of p53

ZFP36 Binds With PRC1 to Inhibit Tumor Growth and Increase 5-Fu Chemosensitivity of Hepatocellular Carcinoma.

ZNF545 Suppresses Human Hepatocellular Carcinoma Growth by Inhibiting NF-kB Signaling.

PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma

Knockdown of ZNF233 Suppresses Hepatocellular Carcinoma Cell Proliferation and Tumorigenesis.

ZNF8 promotes progression of gastrointestinal cancers via a p53-dependent mechanism

The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity

Zinc fingers and homeoboxes 2 is required for diethylnitrosamine-induced liver tumor formation in C57BL/6 mice

ZNF500 abolishes breast cancer proliferation and sensitizes chemotherapy by stabilizing P53 via competing with MDM2

ZNF774 is a Potent Suppressor of Hepatocarcinogenesis Through Dampening the NOTCH2 Signaling.

PPDPF suppresses the development of hepatocellular carcinoma through TRIM21-mediated ubiquitination of RIPK1

Mice Deficient in the RNA-Binding Protein Zfp871 Are Prone to Early Death and Steatohepatitis in Part through the p53-Mdm2 Axis

Peroxisome Proliferator Activated Receptor Alpha Inhibits Hepatocarcinogenesis Through Mediating NF-κB Signaling Pathway.

ZNF281 inhibits mitochondrial biogenesis to facilitate metastasis of hepatocellular carcinoma

Zinc-finger Protein P52-Zer6 Accelerates Colorectal Cancer Cell Proliferation and Tumour Progression Through Promoting P53 Ubiquitination.